Top Developed HIV Therapeutics Markets Examined by GBI Research in In-demand Research Report Available at MarketPublishers.com
15 May 2014 • by Natalie Aster
LONDON – Over 34 million people the world over are infected with the human immunodeficiency virus (HIV). The market for HIV therapeutics in the top seven markets is projected to grow from a value of USD 14.3 billion in 2012 to USD 16.3 billion by 2019-end, posting growth of nearly 2% during the forecast period. However, patent expirations, limited HIV drug pipeline efficacy improvement, stringent healthcare expenditure are likely to restrain the growth in the sector.
Current therapy for HIV involves the use of 3 or 4 antiretroviral agents which target different viral replication sites. However, these drugs cannot cure HIV because the virus is integrated into the DNA of host cells and may reside in compartments (viral reservoirs) that the medications cannot reach. Furthermore, though these novel antiretroviral regimens have turned out to be efficacious, safe, and relatively easy to take, with minimal adverse impact on a patient's life quality, long-term toxicities may restrict their use. Hence, today there is a pressing need for a treatment protecting the immune system, decreasing the chronic inflammation and the immune activation. The promising candidates in pipeline today include, among others, Shionogi-ViiV Healthcare’s 572-Trii; Gilead’s Elvitegravir/Cobicistat/Emtricitabine/Tenofovir (Stribild), Avexa’s Apricitabine, Bristol-Myers Squibb’s Censavudine, and Tobira Therapeutics’s Cenicriviroc.
In-demand report “HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth” created by GBI Research provides true insights into the HIV therapeutics market in the 8 leading markets (the US, the UK, Italy, Germany, France, Spain, Canada and Japan), along with detailed market forecasts to 2019. It investigates the major marketed drugs, besides peering into the R&D pipeline for HIV. The study provides a keen look at the unmet needs, barriers & drivers that are affecting the market globally. A deep discussion of the pipeline for all the HIV molecules across different development stages is included. The competitive scene is scrutinised, and the key deals, licensing and co-development, are reviewed in the research report.
HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth
Published: April, 2014
Price: US$ 3,500.00
More in-demand studies by the publisher can be found at GBI Research page.